About Aqemia
Aqemia is a company based in Paris (France) founded in 2019 by Maximilien Levesque. Aqemia has raised $102.82 million across 5 funding rounds from investors including Eurazeo, Bpifrance and Wendel. Aqemia offers products and services including AI Drug Discovery Platform and Quantum Physics Algorithms. Aqemia operates in a competitive market with competitors including NTxBio, Nimble Therapeutics, Applied BioMath, Enveda and IMIDomics, among others.
- Headquarter Paris, France
- Founders Maximilien Levesque
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$102.82 M (USD)
in 5 rounds
-
Latest Funding Round
$7.4 M (USD), Grant
Apr 01, 2025
-
Investors
Eurazeo
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aqemia
Aqemia offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform and Quantum Physics Algorithms.
Uses AI and quantum physics to generate drug candidates rapidly.
Algorithms that produce data for early-stage drug discovery projects.
People of Aqemia
Unlock access to complete
Funding Insights of Aqemia
Aqemia has successfully raised a total of $102.82M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $7.4 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aqemia
Aqemia has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurazeo, Bpifrance and Wendel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in technology startups through a global ecosystem.
|
Locked | Locked | Locked | |
|
Private equity and funds of funds focused on industrial, media, energy, healthcare, biotechnology, and multiple sectors
|
Locked | Locked | Locked | |
|
Private equity and debt investments are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Aqemia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aqemia
Investment portfolio details for Aqemia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aqemia
Detailed financials for Aqemia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aqemia Comparisons
Peer comparison for Aqemia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aqemia
Aqemia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NTxBio, Nimble Therapeutics, Applied BioMath, Enveda and IMIDomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of bio informatics platform to develops biologics and therapeutics
|
|
| Locked | Locked | Locked |
Combinatorial chemistry services for peptide-based drug discovery are provided.
|
|
| Locked | Locked | Locked |
Systems biology and pharmacology modeling services to aid drug discovery and development
|
|
| Locked | Locked | Locked |
Provider of AI-based platform to decipher the chemistry of nature and develop new medicines
|
|
| Locked | Locked | Locked |
Precision medicines for immune-mediated inflammatory diseases are developed.
|
Detailed competitors of Aqemia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aqemia
Complete news archive for Aqemia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aqemia
Aqemia was founded in 2019.
Aqemia is headquartered in Paris, France.
Maximilien Levesque is the current CEO of Aqemia. They have also founded this company.
Aqemia is a funded company, having raised a total of $102.82M across 5 funding rounds to date.
Aqemia was founded in 2019 in Paris, France, as a provider of AI-driven software combined with quantum physics for therapeutic molecule discovery. Small molecules are screened using AI-based technology to assess physical properties, supporting upstream processing and drug development. Therapeutic targets linked to specific diseases are identified. Operations focus on biotechnology and pharmaceuticals, aiding research in molecular screening and target validation across global collaborations.
Aqemia offers AI Drug Discovery Platform and Quantum Physics Algorithms.
Aqemia has 6 investors. Key investors include Eurazeo, Bpifrance, Wendel, unknown, and Cathay Innovation.